NUEVOLUTION A/S
Nøgletal
- Afkastningsgrad
- 18,8 %
- Egenkapitalforrentning
- 44,4 %
- Likviditetsgrad
- 122,5 %
- Soliditetsgrad
- 37,6 %
Resultat
| Regnskabsperiode | |
|---|---|
Omsætning | 203.323.000 |
Driftsresultat | 44.773.000 |
Finansielle indtægter | 0 |
Finansielle omkostninger | 4.522.000 |
Skat af årets resultat | 497.000 |
Årets resultat | 39.754.000 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 80 |
Balance
| Regnskabsperiode | |
|---|---|
Kortfristede aktiver | 162.345.000 |
Langfristede aktiver | 75.695.000 |
Aktiver i alt | 238.040.000 |
Egenkapital | 89.493.000 |
Forpligtelser i alt | 148.547.000 |
Kortfristede forpligtelser | 132.575.000 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Andre kortfristede tilgodehavender | 5.129.000 |
Leverandørgæld | 8.656.000 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 16.500.000 |
Overført resultat | -212.402.000 |
Højdepunkter fra årsrapporten
Forretning og udvikling
Company and research and development activitiesNuevolution A/S is a Danish biopharmaceutical company focused on developing drug treatments for human
disease within oncology, inflammatory diseases and cardiometabolic diseases.…
Development in activities and financial mattersRevenue for the year amounts to TDKK 203,323 compared to TDKK 118,442 in 2024 and operating result for the
year amounts to TDKK 44,773 compared to TDKK -26,919 in 2024. In the annual report for 2024, Management…
Risici og væsentlige forhold
17 Funding and Going ConcernIn October 2016, Nuevolution entered into a research collaboration with Amgen, a multi target research
collaboration in which Amgen has an exclusive option to obtain all rights to successfully developed…
The CEO Alex Haahr Gouliaev will step down from his position by the end of June 2026. His position will be
taken over by Thomas Franch. No other subsequent event with significant effect on the annual report for 2025
has occurred after the balance sheet date.
16 Significant events after the balance sheet dateThe CEO Alex Haahr Gouliaev will step down from his position by the end of June 2026. His position will
be taken over by Thomas Franch. No other subsequent event with significant effect on the annual report
for 2025 has occurred after the balance sheet date.
Forpligtelser og sikkerhedsstillelser
15 Contingent assets and liabilitiesLicense and Collaboration AgreementsWe are entitled to potential milestone payments and royalties on successful commercialization of product
developed under license and collaboration agreements with our collaboration partners. Since the size and…
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger